Drs. Issa and Bunick dive into the possible mechanistic explanations behind arthralgia associated with dupilumab, which was detailed in a case series by Drs. Issa and Bunick and their colleagues in the May issue of The Journal of Clinical and Aesthetic Dermatology. Listen here to an extended podcast version of this journal review episode.
Time Stamps:
[0:00] Introduction
[1:23] Chapter 1: Dr. Issa’s initial clinical takeaways from the paper
[2:59] Chapter 2: Mechanism of action of dupilumab versus tralokinumab versus lebrikizumab
[6:44] Chapter 3: Immune phenotype cytokine skewing in atopic dermatitis
[7:54] Chapter 4: Mechanistic explanation for arthralgia in patients receiving dupilumab for atopic dermatitis
[9:24] Chapter 5: Possible mechanistic explanation for patient outlier in case series who maintained arthralgia following a switch from dupilumab to lebrikizumab, but resolved after switching to tralokinumab
[10:26] Chapter 6: Th-17 skewing as a mechanistic connection between dupilumab-associated arthralgia and conjunctivitis in patients with AD
[14:09] Chapter 7: Final clinical takeaways
Reference:
- Greenberg ABW, Shahriari M, Cameron, et al. Tralokinumab as a Therapeutic Alternative for Dupilumab-associated Arthralgia in Atopic Dermatitis: A Multi-center Case Series. J Clin Aesthet Dermatol. 2025;18(5):16–19.